drugset / Trial / NCT00421369

Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.

NCT00421369

Completed 35 enrolled Hadassah Medical Organization
Non-randomizedSingle-groupOpen-labelTreatment

Summary

In this project we aim to further refine indications for the use of the thyroid hormone - T3 for patients suffering from depression. We aim to identify a sub-group of patients who are more likely to respond to T3 and establish the time in the treatment course when T3 should be added. The results of this project could have significant, direct clinical implications.

Timeline

Start
2007-09
Primary completion
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Liothyronine Small molecule
Subject Reboxetine Unknown
Background Sertraline Small molecule